Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBT Margin (2022 - 2025)

Historic EBT Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to 7.55%.

  • Arcutis Biotherapeutics' EBT Margin rose 1003600.0% to 7.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.62%, marking a year-over-year increase of 1271000.0%. This contributed to the annual value of 70.92% for FY2024, which is 3636400.0% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its EBT Margin stood at 7.55% for Q3 2025, which was up 1003600.0% from 19.07% recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year EBT Margin high stood at 7.55% for Q3 2025, and its period low was 14856.41% during Q3 2022.
  • Its 4-year average for EBT Margin is 1735.59%, with a median of 139.14% in 2023.
  • Per our database at Business Quant, Arcutis Biotherapeutics' EBT Margin surged by 147172700bps in 2023 and then surged by 330900bps in 2025.
  • Arcutis Biotherapeutics' EBT Margin (Quarter) stood at 2432.25% in 2022, then soared by 80bps to 489.86% in 2023, then soared by 97bps to 14.67% in 2024, then soared by 151bps to 7.55% in 2025.
  • Its last three reported values are 7.55% in Q3 2025, 19.07% for Q2 2025, and 37.63% during Q1 2025.